Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Brisson

Showing results (121-130 of 145) with videos related to

Pageof 15
Sort By:
The Lancet. Infectious Diseases|September 24, 2022
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control studySara Carazo, Danuta M Skowronski, Marc Brisson, et al.
BMC Public Health|May 23, 2022
Time trends in social contacts before and during the COVID-19 pandemic: the CONNECT studyMélanie Drolet, Aurélie Godbout, Myrto Mondor, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2021
Single-Dose Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative Design From Québec, CanadaSara Carazo, Denis Talbot, Nicole Boulianne, et al.
JAMA Network Open|October 14, 2022
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, CanadaSara Carazo, Danuta M Skowronski, Marc Brisson, et al.
Human Vaccines & Immunotherapeutics|June 12, 2019
Assessment of population immunity to measles in Ontario, Canada: a Canadian Immunization Research Network (CIRN) studyShelly Bolotin, Alberto Severini, Todd Hatchette, et al.
Vaccine|May 1, 2022
Population immunity to measles in Canada using Canadian Health Measures survey data - A Canadian Immunization Research Network (CIRN) studySelma Osman, Natasha Crowcroft, Elizabeth McLachlan, et al.
Vaccine|June 28, 2019
An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-ToolSteven E Bellan, Rosalind M Eggo, Pierre-Stéphane Gsell, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|February 15, 2022
Geographic concentration of SARS-CoV-2 cases by social determinants of health in metropolitan areas in Canada: a cross-sectional studyYiqing Xia, Huiting Ma, Gary Moloney, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|December 8, 2020
Jonathon R Campbell, Aashna Uppal, Olivia Oxlade, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 10, 2020
Active testing of groups at increased risk of acquiring SARS-CoV-2 in Canada: costs and human resource needsJonathon R Campbell, Aashna Uppal, Olivia Oxlade, et al.
Pageof 15

Showing results (121-130 of 145) with videos related to

Sort By:
Pageof 15
The Lancet. Infectious Diseases|September 24, 2022
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control studySara Carazo, Danuta M Skowronski, Marc Brisson, et al.
BMC Public Health|May 23, 2022
Time trends in social contacts before and during the COVID-19 pandemic: the CONNECT studyMélanie Drolet, Aurélie Godbout, Myrto Mondor, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2021
Single-Dose Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative Design From Québec, CanadaSara Carazo, Denis Talbot, Nicole Boulianne, et al.
JAMA Network Open|October 14, 2022
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, CanadaSara Carazo, Danuta M Skowronski, Marc Brisson, et al.
Human Vaccines & Immunotherapeutics|June 12, 2019
Assessment of population immunity to measles in Ontario, Canada: a Canadian Immunization Research Network (CIRN) studyShelly Bolotin, Alberto Severini, Todd Hatchette, et al.
Vaccine|May 1, 2022
Population immunity to measles in Canada using Canadian Health Measures survey data - A Canadian Immunization Research Network (CIRN) studySelma Osman, Natasha Crowcroft, Elizabeth McLachlan, et al.
Vaccine|June 28, 2019
An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-ToolSteven E Bellan, Rosalind M Eggo, Pierre-Stéphane Gsell, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|February 15, 2022
Geographic concentration of SARS-CoV-2 cases by social determinants of health in metropolitan areas in Canada: a cross-sectional studyYiqing Xia, Huiting Ma, Gary Moloney, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|December 8, 2020
Jonathon R Campbell, Aashna Uppal, Olivia Oxlade, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 10, 2020
Active testing of groups at increased risk of acquiring SARS-CoV-2 in Canada: costs and human resource needsJonathon R Campbell, Aashna Uppal, Olivia Oxlade, et al.
Pageof 15